HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 286/3/F572    most recent 00190.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Li, S. Articles by Portilla, D. Search for Related Content PubMed PubMed Citation Articles by Li, S. Articles by Portilla, D.

PPAR ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity

¹Division of Nephrology, Department of Internal Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205; ²Department of Biochemistry and Molecular Biology, Indiana University, Indianapolis, Indiana 46202; and ³Department of Pathology, Duke University, Durham, North Carolina 27710

Submitted 16 May 2003 ; accepted in final form 10 November 2003

Previous studies demonstrated that during cisplatin-induced acute renal failure, there is a significant reduction in proximal tubule fatty acid oxidation. We now report on the effects of peroxisome proliferator-activated receptor- (PPAR) ligand Wy-14643 (WY) on the abnormalities of medium chain fatty acid oxidation and pyruvate dehydrogenase complex (PDC) activity in kidney tissue of cisplatin-treated mice. Cisplatin causes a significant reduction in mRNA levels and enzyme activity of mitochondrial medium chain acyl-CoA dehydrogenase (MCAD). PPAR ligand WY ameliorated cisplatin-induced acute renal failure and prevented cisplatin-induced reduction of mRNA levels and enzyme activity of MCAD. In contrast, in cisplatin-treated PPAR null mice, WY did not protect kidney function and did not reverse cisplatin-induced decreased expression of MCAD. Cisplatin inhibited renal PDC activity before the development of acute tubular necrosis, and PDC inhibition was reversed by pretreatment with PPAR agonist WY. Cisplatin also induced increased mRNA and protein levels of pyruvate dehydrogenase kinase-4 (PDK4), and PPAR ligand WY prevented cisplatin-induced increased expression of PDK4 protein levels in wild-type mice. We conclude that PPAR agonists have therapeutic potential for cisplatin-induced acute renal failure. Use of PPAR ligands prevents acute tubular necrosis by ameliorating cisplatin-induced inhibition of two distinct metabolic processes, MCAD-mediated fatty acid oxidation and PDC activity.

peroxisome proliferator-activated receptor-; pyruvate dehydrogenase complex; fatty acid oxidation

This article has been cited by other articles:

				H. Liu, Z. Jia, S. Soodvilai, G. Guan, M.-H. Wang, Z. Dong, J. D. Symons, and T. Yang Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury Am J Physiol Renal Physiol, October 1, 2008; 295(4): F942 - F949. [Abstract] [Full Text] [PDF]

				L. Baud and E. Letavernier PPAR{alpha} Contributes to Tubular Protection J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3017 - 3018. [Full Text] [PDF]

				T. Feldkamp, A. Kribben, N. F. Roeser, T. Ostrowski, and J. M. Weinberg Alleviation of fatty acid and hypoxia-reoxygenation-induced proximal tubule deenergization by ADP/ATP carrier inhibition and glutamate Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1606 - F1616. [Abstract] [Full Text] [PDF]

				H. Boulanger, R. Mansouri, J. F. Gautier, and D. Glotz Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies? Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2696 - 2702. [Full Text] [PDF]

				A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas PPAR-{alpha} and -{gamma} agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2399 - 2405. [Abstract] [Full Text] [PDF]

				M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]

				T. Feldkamp, A. Kribben, N. F. Roeser, R. A. Senter, and J. M. Weinberg Accumulation of nonesterified fatty acids causes the sustained energetic deficit in kidney proximal tubules after hypoxia-reoxygenation Am J Physiol Renal Physiol, February 1, 2006; 290(2): F465 - F477. [Abstract] [Full Text] [PDF]

				S. Li, N. Gokden, M. D. Okusa, R. Bhatt, and D. Portilla Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF Am J Physiol Renal Physiol, August 1, 2005; 289(2): F469 - F480. [Abstract] [Full Text] [PDF]

				S. Li, R. Bhatt, J. Megyesi, N. Gokden, S. V. Shah, and D. Portilla PPAR-{alpha} ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G Am J Physiol Renal Physiol, November 1, 2004; 287(5): F990 - F998. [Abstract] [Full Text] [PDF]